PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27556820-8 2018 Furthermore, in vitro experiments showed that withaferin-A, a chemical inhibitor of vimentin, could inhibit GBM cell migration and invasion activity when its concentrations were <0.5 muM, and higher concentrations of withaferin-A could decrease the viability of U251and U87 cells significantly. withaferin A 46-58 vimentin Homo sapiens 84-92 30699149-2 2019 Here we report that inhibition of vimentin using the steroidal lactone Withaferin A (WFA) causes vimentin to aggregate, and this is associated with the relocalisation of organelles including autophagosomes and lysosomes from the cytosol to a juxtanuclear location. withaferin A 71-83 vimentin Homo sapiens 34-42 30699149-2 2019 Here we report that inhibition of vimentin using the steroidal lactone Withaferin A (WFA) causes vimentin to aggregate, and this is associated with the relocalisation of organelles including autophagosomes and lysosomes from the cytosol to a juxtanuclear location. withaferin A 71-83 vimentin Homo sapiens 97-105 30699149-2 2019 Here we report that inhibition of vimentin using the steroidal lactone Withaferin A (WFA) causes vimentin to aggregate, and this is associated with the relocalisation of organelles including autophagosomes and lysosomes from the cytosol to a juxtanuclear location. withaferin A 85-88 vimentin Homo sapiens 34-42 30699149-2 2019 Here we report that inhibition of vimentin using the steroidal lactone Withaferin A (WFA) causes vimentin to aggregate, and this is associated with the relocalisation of organelles including autophagosomes and lysosomes from the cytosol to a juxtanuclear location. withaferin A 85-88 vimentin Homo sapiens 97-105 31569795-5 2019 Treatments with withaferin A or acrylamide show that cell motility can be modulated by regulating vimentin assembly. withaferin A 16-28 vimentin Homo sapiens 98-106 30267961-4 2019 Treatment of cells with the vimentin-targeting steroidal lactone withaferin A had no effect on vimentin turnover as previously reported, instead causing NEDD9 cleavage and cell death. withaferin A 65-77 vimentin Homo sapiens 28-36 27556820-8 2018 Furthermore, in vitro experiments showed that withaferin-A, a chemical inhibitor of vimentin, could inhibit GBM cell migration and invasion activity when its concentrations were <0.5 muM, and higher concentrations of withaferin-A could decrease the viability of U251and U87 cells significantly. withaferin A 220-232 vimentin Homo sapiens 84-92 26795472-1 2016 Withaferin A (WFA), initially identified as a compound that inhibits experimental angiogenesis, has been shown to bind to soluble vimentin (sVim) and other type III intermediate filament (IF) proteins. withaferin A 0-12 vimentin Homo sapiens 130-138 27942003-6 2016 Disruption of vimentin intermediate filaments by withaferin A reduced E to 0.92 kPa. withaferin A 49-61 vimentin Homo sapiens 14-22 29623041-2 2018 Inadequate therapy motivated us to explore the effect of vimentin inhibitor Withaferin A, as an anti-fibrotic agent against TGF-beta1-induced in vitro fibrotic events and Bleomycin induced in vivo fibrosis with an emphasis on epithelial to mesenchymal transition (EMT), extracellular matrix deposition (ECM), inflammation, and angiogenesis. withaferin A 76-88 vimentin Homo sapiens 57-65 26795472-1 2016 Withaferin A (WFA), initially identified as a compound that inhibits experimental angiogenesis, has been shown to bind to soluble vimentin (sVim) and other type III intermediate filament (IF) proteins. withaferin A 14-17 vimentin Homo sapiens 130-138 25448402-5 2015 Disruption of vimentin cytoskeleton by treatment with withaferin A, a natural steroidal lactone, suppressed not only the adhesion of ATL cells to the feeder layer but also subsequent Ad-MCA formation by ATL cells, suggesting the involvement of vimentin in anchoring ATL cells to the feeder layer. withaferin A 54-66 vimentin Homo sapiens 14-22 24293234-0 2015 Withaferin A inhibits experimental epithelial-mesenchymal transition in MCF-10A cells and suppresses vimentin protein level in vivo in breast tumors. withaferin A 0-12 vimentin Homo sapiens 101-109 26292717-5 2015 Following chromobody fluorescence in a cancer-relevant cellular model, we were able for the first time to monitor and quantify dynamic changes of endogenous vimentin upon siRNA-mediated knockdown, induction with TGF-beta and modification with Withaferin A by high-content imaging. withaferin A 243-255 vimentin Homo sapiens 157-165 25448402-5 2015 Disruption of vimentin cytoskeleton by treatment with withaferin A, a natural steroidal lactone, suppressed not only the adhesion of ATL cells to the feeder layer but also subsequent Ad-MCA formation by ATL cells, suggesting the involvement of vimentin in anchoring ATL cells to the feeder layer. withaferin A 54-66 vimentin Homo sapiens 244-252 21083634-6 2011 E. coli-induced PMN transmigration was markedly inhibited by withaferin A, a dual inhibitor of vimentin and proteasome. withaferin A 61-73 vimentin Homo sapiens 95-103 24069380-2 2013 Withaniasomnifera root extracts (WRE) have anti-proliferative activity and the active component, Withaferin A, inhibits the pro-metastatic protein, vimentin. withaferin A 97-109 vimentin Homo sapiens 148-156 22900077-6 2012 Vimentin is a primary target of Withaferin-A (WF-A). withaferin A 32-44 vimentin Homo sapiens 0-8 24648251-4 2014 Withaferin A (WFA), a vimentin targeting drug is shown to disrupt endothelial barrier function through its effects on vimentin filament distribution and physical properties. withaferin A 0-12 vimentin Homo sapiens 22-30 24648251-4 2014 Withaferin A (WFA), a vimentin targeting drug is shown to disrupt endothelial barrier function through its effects on vimentin filament distribution and physical properties. withaferin A 0-12 vimentin Homo sapiens 118-126 24648251-4 2014 Withaferin A (WFA), a vimentin targeting drug is shown to disrupt endothelial barrier function through its effects on vimentin filament distribution and physical properties. withaferin A 14-17 vimentin Homo sapiens 22-30 24648251-4 2014 Withaferin A (WFA), a vimentin targeting drug is shown to disrupt endothelial barrier function through its effects on vimentin filament distribution and physical properties. withaferin A 14-17 vimentin Homo sapiens 118-126 24952458-6 2014 Although, molecular mechanisms of actin and vimentin disruption by the applied cytoskeletal drugs, Cytochalasin-D and Withaferin-A, are different, cell softening in both cases can be attributed to reduction of the effective density and stiffness of filament networks. withaferin A 118-130 vimentin Homo sapiens 44-52 24952458-11 2014 These insights add functional cues to frequently observed overexpression of vimentin in diverse types of cancer and underline the role of vimentin targeting drugs, such as Withaferin-A, as a potent cancerostatic supplement. withaferin A 172-184 vimentin Homo sapiens 76-84 24952458-11 2014 These insights add functional cues to frequently observed overexpression of vimentin in diverse types of cancer and underline the role of vimentin targeting drugs, such as Withaferin-A, as a potent cancerostatic supplement. withaferin A 172-184 vimentin Homo sapiens 138-146 24478454-7 2014 The requirement for vimentin in repair cell function is revealed by both small interfering RNA vimentin knockdown and exposure to the vimentin-targeted drug withaferin A. withaferin A 157-169 vimentin Homo sapiens 20-28 22720028-1 2012 Withaferin A (WFA) is a steroidal lactone present in Withania somnifera which has been shown in vitro to bind to the intermediate filament protein, vimentin. withaferin A 0-12 vimentin Homo sapiens 148-156 22720028-1 2012 Withaferin A (WFA) is a steroidal lactone present in Withania somnifera which has been shown in vitro to bind to the intermediate filament protein, vimentin. withaferin A 14-17 vimentin Homo sapiens 148-156 32585813-4 2020 Here, we evaluate whether Withaferin-A (WFA), an established disruptor of vimentin filaments, can also be used to modulate keratin filament assembly. withaferin A 26-38 vimentin Homo sapiens 74-82 32585813-4 2020 Here, we evaluate whether Withaferin-A (WFA), an established disruptor of vimentin filaments, can also be used to modulate keratin filament assembly. withaferin A 40-43 vimentin Homo sapiens 74-82 32585813-5 2020 Our results show that in keratinocytes, which are keratin-rich but vimentin-absent, Withaferin-A disrupts keratin filaments. withaferin A 84-96 vimentin Homo sapiens 67-75 31564085-8 2020 Furthermore, withaferin A was used to study regulation of vimentin expression and its significance in sorafenib resistance. withaferin A 13-25 vimentin Homo sapiens 58-66 31564085-10 2020 Interestingly, the study demonstrated that withaferin A further lowered the expression of vimentin in HepG2 (R) cells in a dose-dependent manner. withaferin A 43-55 vimentin Homo sapiens 90-98